These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32901297)

  • 1. Adherence to cysteamine in nephropathic cystinosis: A unique electronic monitoring experience for a better understanding. A prospective cohort study: CrYSTobs.
    Gaillard S; Roche L; Lemoine S; Deschênes G; Morin D; Vianey-Saban C; Acquaviva-Bourdain C; Ranchin B; Bacchetta J; Kassai B; Nony P; Bodénan E; Laudy V; Rouges C; Zarrabian S; Subtil F; Mercier C; Cochat P; Bertholet-Thomas A
    Pediatr Nephrol; 2021 Mar; 36(3):581-589. PubMed ID: 32901297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between age at initiation of cysteamine treatment, adherence with therapy, and glomerular kidney function in infantile nephropathic cystinosis.
    Nießl C; Boulesteix AL; Oh J; Palm K; Schlingmann P; Wygoda S; Haffner D; Wühl E; Tönshoff B; Buescher A; Billing H; Hoppe B; Zirngibl M; Kettwig M; Moeller K; Acham-Roschitz B; Arbeiter K; Bald M; Benz M; Galiano M; John-Kroegel U; Klaus G; Marx-Berger D; Moser K; Mueller D; Patzer L; Pohl M; Seitz B; Treikauskas U; von Vigier RO; Gahl WA; Hohenfellner K
    Mol Genet Metab; 2022 Aug; 136(4):268-273. PubMed ID: 35835062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cysteamine (Cystagon®) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adults.
    Ariceta G; Lara E; Camacho JA; Oppenheimer F; Vara J; Santos F; Muñoz MA; Cantarell C; Gil Calvo M; Romero R; Valenciano B; García-Nieto V; Sanahuja MJ; Crespo J; Justa ML; Urisarri A; Bedoya R; Bueno A; Daza A; Bravo J; Llamas F; Jiménez Del Cerro LA
    Nephrol Dial Transplant; 2015 Mar; 30(3):475-80. PubMed ID: 25348508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults.
    Brodin-Sartorius A; Tête MJ; Niaudet P; Antignac C; Guest G; Ottolenghi C; Charbit M; Moyse D; Legendre C; Lesavre P; Cochat P; Servais A
    Kidney Int; 2012 Jan; 81(2):179-89. PubMed ID: 21900880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of compliance to oral cysteamine treatment on the costs of Kidney failure in patients with nephropathic cystinosis in the United Kingdom.
    Lashilola S; Xu W; Azimpour K; McCarthy M; Carlot S; Game D; van der Voort J
    BMC Nephrol; 2023 Nov; 24(1):351. PubMed ID: 38031005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.
    Bouazza N; Tréluyer JM; Ottolenghi C; Urien S; Deschenes G; Ricquier D; Niaudet P; Chadefaux-Vekemans B
    Orphanet J Rare Dis; 2011 Dec; 6():86. PubMed ID: 22195601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma chitotriosidase enzyme activity as a novel therapeutic monitor for cysteamine treatment in nephropathic cystinosis: A retrospective validation study.
    Veys K; Elmonem MA; van den Heuvel L; Gahl WA; Levtchenko E
    Mol Genet Metab; 2024 May; 142(1):108454. PubMed ID: 38603816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy.
    Gahl WA; Balog JZ; Kleta R
    Ann Intern Med; 2007 Aug; 147(4):242-50. PubMed ID: 17709758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chitotriosidase as a Novel Biomarker for Therapeutic Monitoring of Nephropathic Cystinosis.
    Veys KRP; Elmonem MA; Van Dyck M; Janssen MC; Cornelissen EAM; Hohenfellner K; Prencipe G; van den Heuvel LP; Levtchenko E
    J Am Soc Nephrol; 2020 May; 31(5):1092-1106. PubMed ID: 32273301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study.
    Bjerre A; Aase SA; Radtke M; Siva C; Gudmundsdottir H; Forsberg B; Woldseth B; Brackman D
    Pediatr Nephrol; 2023 Nov; 38(11):3671-3679. PubMed ID: 37219641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis.
    Medic G; van der Weijden M; Karabis A; Hemels M
    Curr Med Res Opin; 2017 Nov; 33(11):2065-2076. PubMed ID: 28692321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of infantile nephropathic cystinosis depends on early intervention, not genotype: A multicenter sibling cohort study.
    Veys K; Zadora W; Hohenfellner K; Bockenhauer D; Janssen MCH; Niaudet P; Servais A; Topaloglu R; Besouw M; Novo R; Haffner D; Kanzelmeyer N; Pape L; Wühl E; Harms E; Awan A; Sikora P; Ariceta G; van den Heuvel B; Levtchenko E
    J Inherit Metab Dis; 2023 Jan; 46(1):43-54. PubMed ID: 36117148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
    Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
    Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to "A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis").
    Langman CB
    Orphanet J Rare Dis; 2023 Jun; 18(1):162. PubMed ID: 37353838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cysteamine in renal transplantation: A report of two patients with nephropathic cystinosis and the successful re-initiation of cysteamine therapy during the immediate post-transplant period.
    Berryhill A; Bhamre S; Chaudhuri A; Concepcion W; Grimm PC
    Pediatr Transplant; 2016 Feb; 20(1):141-5. PubMed ID: 26477696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.
    Nesterova G; Williams C; Bernardini I; Gahl WA
    Pediatr Nephrol; 2015 Jun; 30(6):945-51. PubMed ID: 25526929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological treatment of nephropathic cystinosis with cysteamine.
    Kleta R; Gahl WA
    Expert Opin Pharmacother; 2004 Nov; 5(11):2255-62. PubMed ID: 15500372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis.
    van Stein C; Klank S; Grüneberg M; Ottolenghi C; Grebe J; Reunert J; Harms E; Marquardt T
    Orphanet J Rare Dis; 2021 Sep; 16(1):387. PubMed ID: 34521447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teenagers and young adults with nephropathic cystinosis display significant bone disease and cortical impairment.
    Bertholet-Thomas A; Claramunt-Taberner D; Gaillard S; Deschênes G; Sornay-Rendu E; Szulc P; Cohen-Solal M; Pelletier S; Carlier MC; Cochat P; Bacchetta J
    Pediatr Nephrol; 2018 Jul; 33(7):1165-1172. PubMed ID: 29435659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety.
    Langman CB; Greenbaum LA; Sarwal M; Grimm P; Niaudet P; Deschênes G; Cornelissen E; Morin D; Cochat P; Matossian D; Gaillard S; Bagger MJ; Rioux P
    Clin J Am Soc Nephrol; 2012 Jul; 7(7):1112-20. PubMed ID: 22554716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.